Omvoh(Mirikizumab-Mrkz)
Medicare prescription drug cost, prescriptions and prescribers, 2024
$1.1M
Medicare cost, 2024
$1.1M
Medicare cost, 2024
Medicare drug plans spent $1.1 million on Omvoh (mirikizumab-mrkz) in 2024, for 107 prescriptions and refills filled by 42 patients. It was first approved in 2023. At about $10,439 per prescription it is a high-cost drug.
Medicare cost, 2024
$1.1M
Prescriptions
107
$10,438.58 per claim
Patients
42
40 prescribers
Total spending
-
All plans
Questions and answers
How much does Medicare spend on Omvoh?
Medicare prescription drug plans paid $1.1M for Omvoh in 2024, for 107 prescriptions and refills to 42 patients. The average cost per claim was $10,438.58.
Which state spends the most on Omvoh?
New York had the highest Medicare cost for Omvoh in 2024: $121K for 11 claims.
Spending over the years
Medicare spending by year
All plans and makers
Prescriber data: cost by year
By state
Where the prescribers practice, 2024
Medicare cost by state
States with the highest cost
Prescriber data by year
| Year | Prescribers | Claims | Patients | Cost |
|---|---|---|---|---|
| 2024 | 40 | 107 | 42 | $1.1M |
Medicaid spending by quarter
Amount reimbursed by state Medicaid programs, all states
Amount reimbursed
Codes
- National drug codes (packages)
- 10
- RxNorm concept IDs
- 2668391, 2668398, 2668405, 2668410, 2680728
- Application numbers
- BLA761279
More drugs: Medicare drug spending and the Prescriptions view.
Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.
Through September 2026, 903 side-effect reports named mirikizumab-mrkz, the active ingredient of Omvoh (reports from 2023 on). 489 of them (54.2%) were serious, 26 named a death and 176 named a hospital stay. The reactions named most often were colitis ulcerative, injection site pain and drug ineffective. 903 reports came in the last 5 years (since 2022).
How to read these numbers
- A report shows that a patient, doctor or drug company suspected a link. It does not prove that the drug caused the effect.
- Counts are not risk rates. They depend on how many people use the drug, how long it has been sold, news and reporting habits, so they do not show which drug is safer.
- The newest months are partial: reports keep arriving late.
Reports, all years
903
318 in 2025 (+1.9% from 2024)
Serious
54.2%
489 reports
Deaths named
26
2.9% of reports
Hospital stays
176
19.5% of reports
Reports by year
Serious reports include those that name a death, a hospital stay, a disability or another serious outcome.
Reports received by year
2026 is the year so far.
Reports naming a death or a hospital stay
One report can name both
Reactions
Reactions named most often
All years. Share = part of all reports in that period. A report can name several reactions.
Patients
As given in the reports; many reports leave sex or age out.
Sex of the patient
All years
Age of the patient
Age when the effect started, all years
Questions and answers
How many side-effect reports name Omvoh?
903 reports from 2023 through September 2026 named mirikizumab-mrkz, the active ingredient of Omvoh. 489 of them (54.2%) were serious, 26 named a death and 176 named a hospital stay.
What are the most reported side effects of Omvoh?
155 reports named colitis ulcerative, the reaction named most often, followed by injection site pain (89) and drug ineffective (81). In the last 5 years the reaction named most often was colitis ulcerative (155 reports). A report can name several reactions.
How many side-effect reports named Omvoh in 2025?
318 reports were received in 2025 (+1.9% from 2024). 2026 so far: 251 reports through September 2026, and more keep arriving late.
Do side-effect reports prove that Omvoh caused a problem?
No. A report shows that a patient, doctor or drug company suspected a link; it does not prove that Omvoh caused the effect. Report counts depend on how widely a drug is used, how long it has been sold, news and reporting habits, so they are not risk rates and do not show which drug is safer.
Related pages
- Other Medicare drug pages with mirikizumab-mrkz: Omvoh Pen, Omvoh*
- Makers on the stock market:
LLY·LLY drug pipeline - Drug approvals (1 approval on file for mirikizumab-mrkz) · Clinical trials · Medicare drug spending
Side-effect reports from official public data, counted per active ingredient (mirikizumab-mrkz) by the year the report was received, so the brand and generic pages of one ingredient show the same reports. A report can name several drugs and several reactions and counts for each. Reaction names are the standard medical terms used in the reports. Reports whose product could not be matched to a drug are not counted. Updated November 2026.